Canaccord Genuity analyst Max Masucci maintained a Buy rating on Genmark Diagnostics on Friday, setting a price target of $24, which is approximately 27.66% above the present share price of $18.8.
Masucci expects Genmark Diagnostics to post earnings per share (EPS) of -$0.05 for the first quarter of 2021.
The current consensus among 3 TipRanks analysts is for a Moderate Buy rating of shares in GenMark (NASDAQ:GNMK), with an average price target of $23.
The analysts price targets range from a high of $24 to a low of $22.
In its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $42.65 million and a net profit of -$1.27 million. The company's market cap is $1.48 billion.
According to TipRanks.com, Canaccord Genuity analyst Max Masucci is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 90.7% and a 85.88% success rate.
GenMark Diagnostics, Inc. is a molecular diagnostics company, which engages in the provision of multiplex molecular diagnostic solutions. Its products include ePlex and XT-8. The company was founded by Jon Faiz Kayyemin 1993 and is headquartered in Carlsbad, CA.